Medicus Pharma Releases Q2 Results; Regulatory Progress for SkinJect and Teverelix

MDCX Medicus Pharma Ltd

$0.10 -36.39%

View chart & analysis →

1. 1Medicus Pharma (MDCX) reported its second-quarter results and corporate update for the period ended June 30, 2026.
2. 2The company reached regulatory milestones, including FDA approval to proceed with the SkinJect registrational trial and IRB approval for the Teverelix Phase 2 study, and has raised approximately $40 million since the start of the year.
3. 3Cash, equivalents and restricted cash stood at $25.2 million as of June 30, and there is substantial doubt about its ability to continue as a going concern without additional funding.

Source ACCESSWIRE +1 · View original ↗

Today's 5 AI picks, all free

Nothing hidden: past picks and how they did against the S&P 500.

See today's picks →